1030 related articles for article (PubMed ID: 17694093)
101. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
102. Rational design and development of radiation-sensitizing histone deacetylase inhibitors.
Jung M; Kozikowski A; Dritschilo A
Chem Biodivers; 2005 Nov; 2(11):1452-61. PubMed ID: 17191946
[TBL] [Abstract][Full Text] [Related]
103. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
[TBL] [Abstract][Full Text] [Related]
104. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW
Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
[TBL] [Abstract][Full Text] [Related]
105. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
Marks PA
Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
[TBL] [Abstract][Full Text] [Related]
106. Histone deacetylase inhibitors as new cancer drugs.
Marks PA; Richon VM; Breslow R; Rifkind RA
Curr Opin Oncol; 2001 Nov; 13(6):477-83. PubMed ID: 11673688
[TBL] [Abstract][Full Text] [Related]
107. Structural biology of human metal-dependent histone deacetylases.
Schapira M
Handb Exp Pharmacol; 2011; 206():225-40. PubMed ID: 21879452
[TBL] [Abstract][Full Text] [Related]
108. Subtype selective substrates for histone deacetylases.
Heltweg B; Dequiedt F; Marshall BL; Brauch C; Yoshida M; Nishino N; Verdin E; Jung M
J Med Chem; 2004 Oct; 47(21):5235-43. PubMed ID: 15456267
[TBL] [Abstract][Full Text] [Related]
109. Inhibition of histone deacetylase as a new mechanism of teratogenesis.
Menegola E; Di Renzo F; Broccia ML; Giavini E
Birth Defects Res C Embryo Today; 2006 Dec; 78(4):345-53. PubMed ID: 17315247
[TBL] [Abstract][Full Text] [Related]
110. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
Bolden JE; Shi W; Jankowski K; Kan CY; Cluse L; Martin BP; MacKenzie KL; Smyth GK; Johnstone RW
Cell Death Dis; 2013 Feb; 4(2):e519. PubMed ID: 23449455
[TBL] [Abstract][Full Text] [Related]
111. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
112. HDACs and HDAC inhibitors in colon cancer.
Mariadason JM
Epigenetics; 2008; 3(1):28-37. PubMed ID: 18326939
[TBL] [Abstract][Full Text] [Related]
113. Histone deacetylases: unique players in shaping the epigenetic histone code.
Thiagalingam S; Cheng KH; Lee HJ; Mineva N; Thiagalingam A; Ponte JF
Ann N Y Acad Sci; 2003 Mar; 983():84-100. PubMed ID: 12724214
[TBL] [Abstract][Full Text] [Related]
114. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Qiu T; Zhou L; Zhu W; Wang T; Wang J; Shu Y; Liu P
Future Oncol; 2013 Feb; 9(2):255-69. PubMed ID: 23414475
[TBL] [Abstract][Full Text] [Related]
115. Factors affecting the substrate specificity of histone deacetylases.
Riester D; Hildmann C; Grünewald S; Beckers T; Schwienhorst A
Biochem Biophys Res Commun; 2007 Jun; 357(2):439-45. PubMed ID: 17428445
[TBL] [Abstract][Full Text] [Related]
116. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
[TBL] [Abstract][Full Text] [Related]
117. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
[TBL] [Abstract][Full Text] [Related]
118. Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans.
Simonetti G; Passariello C; Rotili D; Mai A; Garaci E; Palamara AT
FEMS Yeast Res; 2007 Dec; 7(8):1371-80. PubMed ID: 17627775
[TBL] [Abstract][Full Text] [Related]
119. Histone deacetylase inhibitors impair antibacterial defenses of macrophages.
Mombelli M; Lugrin J; Rubino I; Chanson AL; Giddey M; Calandra T; Roger T
J Infect Dis; 2011 Nov; 204(9):1367-74. PubMed ID: 21921209
[TBL] [Abstract][Full Text] [Related]
120. Histone deacetylase inhibitors: discovery and development as anticancer agents.
Marks PA; Dokmanovic M
Expert Opin Investig Drugs; 2005 Dec; 14(12):1497-511. PubMed ID: 16307490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
